← Back to Clinical Trials
Recruiting NCT06613594

NCT06613594 Effects of Kaltenborn Translatoric Glides As Compared to Traction Mobilization in the Management of Frozen Shoulder

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06613594
Status Recruiting
Phase
Sponsor Foundation University Islamabad
Condition Adhesive Capsulitis
Study Type INTERVENTIONAL
Enrollment 75 participants
Start Date 2024-08-20
Primary Completion 2024-12-01

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Conventional physical therapyKaltenborn traction mobilizationKaltenborn translatoric glides

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 75 participants in total. It began in 2024-08-20 with a primary completion date of 2024-12-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Frozen shoulder is a common musculoskeletal condition. Painful gradual loss of both active and passive gleno-humeral motion resulting from progressive fibrosis and ultimate contracture of the gleno-humeral joint capsule.Range of motions and capsular pattern affected in frozen shoulder. Physiotherapists have a wide range of options in managing frozen shoulder including Electrotherapeutic modalities, kaltenborn mobilization, Maitland's mobilization,Mulligan's mobilization and Manipulation. So far studies have shown the efficacy of different treatments in combination or in isolation.some studies on Kaltenborn mobilization , but no obseved comparative effects of Kaltenborn mobilization i.e translatoric glides and traction mobilzation in patients with frozen shoulder.In clinically both techniques of kaltenborn are used but there is no evidence regarding which one is more effective. .If found effective,this study can help to use best clinical treatment in the managemnent of frozen shoulder.

Eligibility Criteria

Inclusion Criteria: * Subjects with Nonspecific frozen shoulder without specific identifiable etiology (i.e. infection, inflammatory disease) * 40-65 years of age both males and females. * Chronic shoulder pain \> 3 months. * Positive capsular pattern. Exclusion Criteria: * Patients with other shoulder joint pathologies, such as fractures or dislocations, glenohumeral instability or rotator cuff pathologies in the affected shoulder. * Subjects who have undergone surgery or have experienced an acute trauma to the shoulder. * Individuals with current or history of neurological disorders (such as stroke, Alzheimer's, or Parkinson's), rheumatologic diseases (such as rheumatoid arthritis or systemic lupus erythematous), or systemic illnesses (such as thyroid disease).

Contact & Investigator

Central Contact

Afifa Zuha, MS-MSKPT*

✉ Afifabhattis123@gmail.com

📞 +92334948496

Frequently Asked Questions

Who can join the NCT06613594 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, up to 65 Years, studying Adhesive Capsulitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06613594 currently recruiting?

Yes, NCT06613594 is actively recruiting participants. Contact the research team at Afifabhattis123@gmail.com for enrollment information.

Where is the NCT06613594 trial being conducted?

This trial is being conducted at Rawalpindi, Pakistan.

Who is sponsoring the NCT06613594 clinical trial?

NCT06613594 is sponsored by Foundation University Islamabad. The trial plans to enroll 75 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology